Aspireo reports positive preliminary data from Somatoprim phase Ib study
The study conducted in a single center was designed to assess the safety, side effect profile in addition to pharmacokinetic and pharmacodynamic profile of varying doses of Somatoprim.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.